Understanding aberrant white matter development in schizophrenia: an avenue for therapy?. (July 2011)

• Record Type: Journal Article
• Authors: Walterfang, Mark; Velakoulis, Dennis; Whitford, Thomas J; Pantelis, Christos
• Is Part Of: Expert review of neurotherapeutics. Volume 11:Number 7(2011)
• Page Start: 971
• Page End: 987
• Publication Date: 2011-07
• Subjects: antipsychotic medication -- dysmyelination -- myelin -- oligodendrocytes -- promyelinative -- schizophrenia -- white matter; Neuropharmacology -- Periodicals; 615.7805
• DOI: 10.1586/ern.11.76
• Languages: English
• ISSNs: 1473-7175

Abstract

Although historically gray matter changes have been the focus of neuropathological and neuroradiological studies in schizophrenia, in recent years an increasing body of research has implicated white matter structures and its constituent components (axons, their myelin sheaths and supporting oligodendrocytes). This article summarizes this body of literature, examining neuropathological, neurogenetic and neuroradiological evidence for white matter pathology in schizophrenia. We then look at the possible role that antipsychotic medication may play in these studies, examining both its role as a potential confounder in studies examining neuronal density and brain volume, but also the possible role that these medications may play in promoting myelination through their effects on oligodendrocytes. Finally, the role of potential novel therapies is discussed.